TapImmune Inc. is Pleased to Announce the Signing of an Exclusive Option Agreement for a New Phase 1 Clinical Program in Brea...
March 19 2014 - 8:45AM
Business Wire
TapImmune Inc. (OTCQB: TPIVD), A clinical stage immunotherapy
company specializing in the development of innovative vaccine
technologies for the treatment of cancer and infectious disease has
signed an exclusive option agreement for a set of unique peptide
epitopes targeting Folate Receptor Alpha in both breast cancer and
ovarian cancer.
Folate receptor alpha is expressed in nearly 50% of breast
cancers and in addition, over 95% of ovarian cancers, for which the
only treatment options are surgery and chemotherapy, leaving a very
important and urgent clinical need for a new therapeutic. Time to
recurrence is relatively short for this type of cancer and survival
prognosis is extremely poor after recurrence. In the US alone,
there are approximately 30,000 ovarian cancer patients newly
diagnosed every year.
A 22 patient Phase 1 clinical trial is underway. The trial is
fully enrolled, closed and Phase 2 advancement will be assessed in
late 2014.
No serious adverse events have occurred to date and more
information and immune response data will be made available over
the course the trial. More information can be seen at
http://clinicaltrials.gov/ct2/show/NCT01606241?term=folate+receptor+alpha&rank=1
This is second late stage Phase 1 clinical trial in the
TapImmune portfolio along with the Her2/neu breast cancer sponsored
trial underway at Mayo Clinic in Rochester MN.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the
development of innovative vaccine technologies for the treatment of
cancer and infectious disease. The Company’s vaccine compositions,
peptide or nucleic acid-based, comprise one or multiple naturally
processed epitopes (NPEs) designed to comprehensively stimulate a
patients’ killer T-cells, helper T-cells and to restore or further
augment antigen presentation by using proprietary nucleic
acid-based expression systems. The Company’s vaccine compositions
may be used as stand-alone medications or in combination with
current treatment modalities. Please visit the Company’s website at
www.tapimmune.com for details.
Forward-Looking Statement Disclaimer: This release
contains forward-looking information within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this news release concerning the Company’s expectations, plans,
business outlook or future performance, and any other statements
concerning assumptions made or expectations as to any future
events, conditions, performance or other matters, are
“forward-looking statements”. Forward-looking statements are by
their nature subject to risks, uncertainties and other factors
which could cause actual results to differ materially from those
stored in such statements. Such risks, uncertainties and factors
include, but are not limited to the risks set forth in the
Company’s most recent Form 10-K and other SEC filings which are
available through EDGAR at www.sec.gov. The Company assumes no
obligation to update the forward-looking statements
For TapImmune Inc.Glynn Wilson, PH.D., 866-359-7541Chairman
& CEO
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From Apr 2024 to May 2024
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From May 2023 to May 2024